
LPV/r (LOPINAVIR/RITONAVIR)



• Six companies are working on the LPV/r formulation, of which:

medicines patent pool

- Three MPP licensees approved: Aurobindo, Hetero and Mylan
- Two additional companies (non-licensees) approved: Cipla and Macleods
- An additional licensee is planning to file in 1st half of 2019
- Currently approved in 40 countries and filed in another 10 countries
 - Total filing coverage: 95.3% of PLHIV in LMICs